Eyepoint Pharmaceuticals (EYPT) Given Daily Media Impact Score of 0.01
Headlines about Eyepoint Pharmaceuticals (NASDAQ:EYPT) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Eyepoint Pharmaceuticals earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 49.6364709773074 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Eyepoint Pharmaceuticals traded up $0.05, hitting $2.20, on Friday, according to MarketBeat Ratings. 246,551 shares of the company were exchanged, compared to its average volume of 269,394. Eyepoint Pharmaceuticals has a twelve month low of $0.93 and a twelve month high of $2.88. The stock has a market capitalization of $116.16 million, a price-to-earnings ratio of -4.23 and a beta of 1.01. The company has a debt-to-equity ratio of 1.57, a current ratio of 0.83 and a quick ratio of 0.83.
Several equities research analysts recently issued reports on EYPT shares. Zacks Investment Research downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 4th. ValuEngine upgraded Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 29th. Finally, HC Wainwright set a $3.00 price objective on Eyepoint Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $4.90.
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.
Further Reading: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.